Comparative Pharmacology
Head-to-head clinical analysis: ALTRENO versus FABIOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTRENO versus FABIOR.
ALTRENO vs FABIOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; believed to involve reduction of hepatic glucose production and improvement of insulin sensitivity via AMPK activation.
Retinoid that binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), inducing differentiation and apoptosis of keratinocytes.
ALTRENO is not a recognized drug. No data available.
FABIOR (tazarotene) foam, 0.1%: Apply a thin layer once daily in the evening to affected areas of the face, scalp, or trunk.
None Documented
None Documented
Terminal elimination half-life is 20-30 hours; steady state reached in 5-7 days.
Terminal elimination half-life is approximately 24-26 hours, supporting once-daily dosing.
Primarily renal (70-80% as unchanged drug), with 10-15% biliary/fecal elimination.
Primarily hepatic metabolism via CYP450; renal excretion of metabolites accounts for <1% of dose as unchanged drug. Fecal elimination is the major route (approximately 90%).
Category C
Category C
Retinoid
Retinoid